HUMA Humacyte, Inc.
$0.45▲ +11.41%
Healthcare
Other
After hours
$0.45▲ +1.37%
Oct 27, 5:46 PM ET
Volume 3.71M
Avg Volume (10D) 6.71M
Key Metrics & Fundamentals
Market Cap
$123.98M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.34 - 1.78
% vs 50 MA
-16.81%
% vs 200 MA
-45.37%
RSI-14
46.9
MACD Histogram
+0.0100
Beta (1Y vs SPY)
2.77
Free Cash Flow
-$22.17M
Gross Rev
$406,000
Gross Profit
-$825,000
EBITDA
-$24.82M
COGS
$1.23M
Operating Exp
$26.17M
Operating Income
-$27.00M
EBIT
-$27.00M
Pretax Income
-$36.80M
Net Income
-$36.80M
EPS (Diluted)
-0.16
Price & Volume History
Loading chart…
Recent News
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
GlobeNewswire · Oct 23, 2026 8:00 AM ET
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
Zacks · Oct 21, 2026 5:00 PM ET
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Zacks · Oct 19, 2026 5:15 PM ET
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
GlobeNewswire · Oct 15, 2026 8:00 AM ET
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks · Oct 13, 2026 5:15 PM ET
Humacyte to Present Phase 3 Dialysis Access Trial Results at ASN Kidney Week
MT Newswires · Oct 12, 2026 8:39 AM ET
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
GlobeNewswire · Oct 12, 2026 8:00 AM ET
Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts
Simply Wall St. · Oct 9, 2026 1:16 AM ET
Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
The Fly · Oct 7, 2026 10:00 AM ET
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Zacks · Oct 6, 2026 5:00 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See HUMA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.